glp-1 drugs for sleep apnea Lilly's weight-loss drug reduces severity in late-stage trials Therapeutic Potential of Glucagon-like Peptide-1
Description
M2 macrophage-membrane camouflaged BBR NPs@Mannose enhance targeting and immune evasion while prolonging circulation half-life in an atherosclerosis mouse model [177]
In some cases, the patient requires a more potent dose after this adjustment
Many patients stay on medication for several months to achieve desired results and then transition to a maintenance plan
The sources for the data on these drugs are rather patchy, making direct comparisons difficult due to incomplete data
Diabetes 1995, 44:1126-1131
27,28 GLP-1 receptor agonists (GLP-1 RAs) have been developed for the treatment of metabolic disorders, including obesity and type 2 diabetes (T2D)
